» Articles » PMID: 7588090

A Guide to the Treatment of Lower Respiratory Tract Infections

Overview
Journal Drugs
Specialty Pharmacology
Date 1995 Jul 1
PMID 7588090
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Acute bronchitis is usually a viral infection which, unless there is a special disposition, does not require antibiotic therapy. For the initial oral chemotherapy of bacterial infections of the lower respiratory tract (chronic bronchitis, pneumonia) the effective and well tolerated cephalosporins, macrolides and amoxicillin plus beta-lactamase-inhibitor are recommended. In complicated cases with severe underlying disease, longer history or frequent exacerbations, quinolones should be given if Gram-negative infections are suspected or if initial therapy with other substances has failed. If Legionella, Mycoplasma or Chlamydia spp., so-called 'atypical' pathogens, are involved, macrolide antibiotics are the therapy of first choice. Special attention should be given to the increase in resistance against cotrimoxazole (trimethoprim-sulfamethoxazole) and tetracyclines. In hospitals where primary pneumonias are treated preferentially by intravenous medication, therapy should be switched to oral antibiotics as soon as feasible (follow-up therapy). For severely ill patients with secondary pneumonia and underlying disease, second generation cephalosporins with aminoglycosides, or monotherapy with third generation cephalosporins are recommended. In very severe, high-risk cases, third generation cephalosporins, combinations with high-dosage quinolones or ureidopenicillins plus beta-lactamase-inhibitors are suitable. Future development in the antibiotic treatment of respiratory infections will follow the current trend of lower dosages, with the clear objective of shortening treatment periods and achieving earlier discharge from hospital.

Citing Articles

Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents?.

Vogel F Drugs. 2002; 62(2):309-17.

PMID: 11817975 DOI: 10.2165/00003495-200262020-00005.


Antibiotics in acute bronchitis: a meta-analysis.

Bent S, Saint S, Vittinghoff E, Grady D Am J Med. 1999; 107(1):62-7.

PMID: 10403354 PMC: 7124195. DOI: 10.1016/s0002-9343(99)00167-9.


Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Langtry H, Brogden R Drugs. 1997; 53(6):973-1004.

PMID: 9179528 DOI: 10.2165/00003495-199753060-00006.


Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Perry C, Brogden R Drugs. 1996; 52(1):125-58.

PMID: 8799689 DOI: 10.2165/00003495-199652010-00009.

References
1.
Tremblay D, Dupront A, Ho C, Coussediere D, Lenfant B . Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. J Antimicrob Chemother. 1990; 26 Suppl E:21-8. DOI: 10.1093/jac/26.suppl_e.21. View

2.
Atherton S, White D . Stomach as source of bacteria colonising respiratory tract during artificial ventilation. Lancet. 1978; 2(8097):968-9. DOI: 10.1016/s0140-6736(78)92530-8. View

3.
. Proceedings of a conference: Clinical pharmacology and efficacy of cefixime. Sonoma, CA, March 20 and 21, 1987. Pediatr Infect Dis J. 1987; 6(10):949-1009. View

4.
Bingen E, Lambert-Zechovsky N, Doit C, Duvignaud P, Georges D, Mariani-Kurkdjian P . Killing kinetics of cefuroxime axetil against Haemophilus influenzae in an in-vitro model simulating serum concentration profiles after oral administration. J Antimicrob Chemother. 1991; 28(4):533-6. DOI: 10.1093/jac/28.4.533. View

5.
James N, Donn K, Collins J, Davis I, Lloyd T, Hart R . Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens. Antimicrob Agents Chemother. 1991; 35(9):1860-3. PMC: 245281. DOI: 10.1128/AAC.35.9.1860. View